In recent studies, we demonstrated that the levels of FOXP1 in skeletal muscle of pancreatic cancer patients are tightly linked with cachexia, with high levels of FOXP1 associated with low skeletal muscularity and increased body weight loss.12 Importantly, we further showed that FoxP1 upregulation in skeletal muscle is not only sufficient to drive muscle wasting and weakness but is required for muscle wasting in a murine model of pancreatic cancer.12,13 However, the biological processes regulated by FoxP1 in skeletal muscle remained largely unknown. The gene discussed is FOXP1; the disease is Cachexia.